Of relevance has been the use of monoclonal antibodies targeting the VEGF pathway for cancer therapy, where studies have shown them to be key inhibitors of tumor angiogenesis during adjuvant, maintenance, or combination therapy against some solid tumors [99,100]. The gene discussed is VEGFA; the disease is neoplasm.